<SEC-DOCUMENT>0000000000-21-012802.txt : 20220314
<SEC-HEADER>0000000000-21-012802.hdr.sgml : 20220314
<ACCEPTANCE-DATETIME>20211021153010
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000000000-21-012802
CONFORMED SUBMISSION TYPE:	UPLOAD
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20211021

FILED FOR:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Blue Water Vaccines Inc.
		CENTRAL INDEX KEY:			0001782107
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		UPLOAD

	BUSINESS ADDRESS:	
		STREET 1:		2041 COURTLAND AVENUE
		CITY:			CINCINNATI
		STATE:			OH
		ZIP:			45212
		BUSINESS PHONE:		646-303-0737

	MAIL ADDRESS:	
		STREET 1:		2041 COURTLAND AVENUE
		CITY:			CINCINNATI
		STATE:			OH
		ZIP:			45212
</SEC-HEADER>
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.pdf
<TEXT>
<PDF>
begin 644 filename1
M)5!$1BTQ+C4*)>+CS],*,2 P(&]B:@H\/"]#;VQO<E-P86-E+T1E=FEC94=R
M87DO4W5B='EP92]);6%G92](96EG:'0@,C0W+T9I;'1E<B]&;&%T941E8V]D
M92]4>7!E+UA/8FIE8W0O5VED=&@@,30R."],96YG=&@@,S8U+T)I='-097)#
M;VUP;VYE;G0@.#X^<W1R96%M"GB<[<&!     ,,@?^K=X 15 0
M
M
M
M
M
M
M
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M"U83J5T@@&P1%G"3H7!4FZX<NV,R$6PM:#;"!>>"GG!Q%%,ZAPK16+#E0+[
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MK:3?LM9=:]I%7O<^\N1EVL52)E3-B5RI732RP&YZQ7L;E9L\(;>$JFY"4DQ
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M[DJ(3BP \P1YT[%F@K@_ABI=CEE6:YUI+I*V?YA>X&ASX6TA(B(B(B(B\M>
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M1$1$KB?C-C1+]9I!-8GU^)I9PNOK:]9018]8[/]M"D8T[_[^OMJ3/#T]I?Y
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M2"6M9RS,,2T@#VF6G&@7I$\=I@Y95F)U(HP0&H*#LJ6&_5PZ[6(I\D54>'^
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M,BF8OXL/\)F50NA!$_M,)@N+H[M&?&UE(Z@*BJWK9FCTTN3,EM[ Q*"&F<+
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MU.;2X:\L," +UER8L;;-RG'?TS$J4XA3/3HJ'-[6%6>;_'@R-0_.;T_N 3P
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M!L3F$8Z"/Z0CMIZ/F444U_X1MHWY]D6]9K[J2O)9W6;L]">PG/4!^607'$6
M+]G."E4'1P9L99#G7#)YUG*GC'.LHV*NM8YD1NIKONR+>2<0IM8P_Z D:ZY4
M S5./MMPI'86WNPKRX6=+56-R+MF:'2[V3:6;J1(MV,Z%WU-X[6LA8=,33+=
MECK7FSW]?HWP5]K89+ 2, ;FFBFU!ARJV32=@NY__\9[67KFEXA](CD/SI[!
M;!!CR]@<FC??__,-(3.2X8>)05KR.Q1B3]RR6^#2GLLQ%,X:/1N+4+CL.%U^
MJ50M^S#C34%_M+4RF7+1OMN?7S.K]E'%L^-/893QZ+T%R9C"(.I@T '(>C<&
M!<X'6X_!I$7SMOK.<&D.+=KZ&-:B9-7EG3O+X1@:!E<*/6J])]NC^^ATNDSO
M/T83Q (A =2D'7ZZ\ #?=[H9PUJ$XIIW.B5]]#YXUF2L$0<@5*I->18_\S2B
M_M]ZRCB91FC0JTLR#?S'V32*@X<,=,ZF (7E 43Z"6I-,)MN5;KE"17!98AX
MAU\MH@X/"*C3C;[CD'>J)3.8)YA#& ?6CF-5(86Z<H#O463<,)SF;88#MC);
M.SR/*<7(ZY (R2+/F6&DG5<JL7>0E'4!5G7RV([/K<"TM.X(MZ^"8_-X6:.(
M0L[7<[EH<#KJ3W^L9NM:EY9"Y1=,4]:ZS@N,6T)E_*B6J<2092>L@2Y,N3?=
M+N,B/G696V,SY.$3#'(OQG:&R$>_[@,HOX@"[<=FA6?5' -]1Q8,D6T-SL&R
MU"*16(4F C0F9YCZ>:G8R5FF-JKIUIB\3_&(SC )O*4;K:6<D'73SC:+E[6!
M<+E\,$,\'OS!Z6/P7Y4E#UN%L+N,P)A+,,U<!OEEUL5S[_D;Z^#TR;K-AI.*
M&A:%;I^#AI<9NO"]RV\63QAZ.CUBZ+JUJT&EF>T9#87*I6F EQ.D :D[^5]R
M)8K_0CD.3A]=P=R]5HTS#-MC*V=FB\;&S;'6'8?^9TP-0U<,SS/U=/H4=3<^
M\K)9Z[W(FSW5]G/%(,"H?\N_E< N<6FWHP[TXYV=1O%VN9%NQX.KO-FK<JR,
M_95#P#5VVE3V3"K<XC(T9>HXP\D]K7_\!8 _2F!0P(Z3\F"R8<R@"(UW.-R,
M*0V2R%7O]>-DUX_9]@[OK(<3Q2SYZ233+<+5$9:S5-F C6E<)@X=UT>T\G2V
MAT^%.<*6(VQG1@R\_!!<7G2G[CHFY#4=\Y2;NKDKC2F+%R<ZYH,_?[RA5WUG
MG+A^>70F86<&6O]F2$/;YD39&%4G8DP/JM=1\%DH!FF ?@QBDF>"T@ $M1-Z
M])?7@G/_S(0>&Q@#5%AT'-X^-![]P,W]QVX*.#J(-O8J-WIJH3%<F_I0/)C&
MIV/:L(4G'3"'N]3EH'\*Y,I^1.*/(%;35FTPK#8T*=#,BK;@5*-/K<=TH8H=
M.@8PX@6B:"&@1PRDP_J#<L#92XSB=Y+'UN'NUQ?0Q#2RHDS?E][D,*(2%> @
MXI: \W4.&50ZLW,6M  /.Z30C7+V\Q!$SU@T(HQIB;7O>U/P?$3;<M4!91 +
MLI6'?<3-[G_*6A^_X?P;3:(/^ IE;F1S=')E86T*96YD;V)J"C$X(# @;V)J
M"CP\+T9I;'1E<B]&;&%T941E8V]D92],96YG=&@@,34U,#X^<W1R96%M"GB<
MS5?)<MM&$+WS*[ITDJLH!(,=N<5RO*BLR);IJ%SERP@8D!-CH68 R<S7\%/3
M/0-*( 3:E@])Y'()P/3T\OKUHIL9 _IW^6KF.@G<S:(4/!8[$50S+_*<R.M?
MR]F'F0NOIL2]<$_<O#Z(WTU<86EJK\2)DP;]ZS<LN/%0W+Y^QT+"S!66NDZ:
M]*^'+; DW1=/#UL(??SIK\4H[M,]'R]$N_<).WN7(L>+AY?,^]#:^]G-[/F"
MA./0@T6.!R<A\YR@?V8)/?SR$M7C<=$;4LO9,;R42K=_\$K 6VX?SAHMUBMX
M+53-ZUS\_6SQ%^I8#B_M/KG@[ED8B)PV%5_S>@.D\GG9";CBK5#P)\\R60L-
M;^K,^3G5%UG;7*,JC\TQMQZ#=WPI(/HQ9=X.B>2[0!RZW;__OD#<$74&](%!
M[$$<^+"H!D ?3X$YO. E=.'X6P -Q9G1?SQ&8"06I5;K R[HZXUAB0=GAC6[
M_^\/?+=G@^B8&SH)@R@.G&04X[:W,"&-)1Z.I'_+<]G*IN9EN9G#NA1<"U#B
M5N*O3=,I>/,.<JFSLM&=$M VD(L" 0&>J:;>5'K+6R@H6=!IX6SA9:.&\>],
M!XG## JRUBVO,S&'.P%UTZ+.%:J0-7!4K3,EU^0/-(7Y<"O*9EV)NH5*ED*W
M#9K&TS5AR5@X)R?)\I1-WW=B8[-=W?N[/;+.9DU5"95)7H+FI2#[EQ=71W G
MVU73M39*62_A"#_/\?M*9BO@Z[7@2D\98ZECV<"7')65ACWXT*ZD!BTR"LKY
MJ>3_5]\?D0[;8PAA&CO>F$6,.0=9%Z9CAE[UB3?\,EQ#;#2!I81>XZ. M9*-
MLDG"U'ON'+!>+5,HX2M^2SKN=M04^41*PL3',;#+_U&%^:RZZ@AXU72H% E6
M='5..:9S[)"F0:Y5<RMSD1/5+[X6C<KA8RUOA=*RW:"/4X:BU/&,H3->=UQM
MJ NX6[R+FI7 0(DT9!"I1L=T\D(Y<*JX7,)BA:8UDIIKI'S6U+8B21Z#%PH]
MG#(:]J6/%86N4@@7']] *3-! /(E&B;PL"07]EA\;0G,+XA;/5GJ>W4^93)P
M:8:AR1XDH[;B7PG7':PF1T- *[Z!:S)TTTEE<5WC)_Q%\%N$IHQY-G<_AIWE
MQ]U*U* [*M3[MD;&"(?/Q_KS,RSOLD1OINPQUK,E[ZB/O>B9!11#P;'%*[TU
MP1D=$H/+;* /?.(UIK\<>DKG2I3BEM?MA-& BJFG*,)P0L'"&E/>Y* ;(H1I
MN$B"BGHN:>O*5E;87![P?H"ZCPZ:ZU(N42:?SF.0>#UU$)LYH)L\)Q8<KN'
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B:51E>'0M-2XT+C4*<W1A<G1X<F5F"C,X,S$X"B4E14]&"@$!

end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo





                               October 21, 2021

       Joseph Hernandez
       Chief Executive Officer
       Blue Water Vaccines Inc.
       201 E. Fifth Street, Suite 1900
       Cincinnati, OH 45202

                                                        Re: Blue Water Vaccines
Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed October 8,
2021
                                                            File No. 333-260137

       Dear Mr. Hernandez:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Form S-1 filed on October 8, 2021

       Pipeline, page 2

   1.                                                   We note your response
to prior comment 4. With respect to your pipeline table on pages
                                                        2, 63 and 77, we
previously noted that the    status    column for the Norovirus/Malaria row
                                                        of the pipeline table
indicates that you plan to start IND-enabling studies for this candidate
                                                        in the second half of
2022, and that such statement appears speculative and premature,
                                                        particularly in light
of your disclosure that your current cash position is sufficient to fund
                                                        your operations only
until Q2 2022 and that your ability to continue as a going concern
                                                        beyond that point is
contingent upon obtaining funding from this offering.

                                                        In your response, you
point out that your revisions on page 4 of prospectus summary state
                                                        your expectation that
your existing cash along with the proceeds of the offering will be
 Joseph Hernandez
FirstName
Blue WaterLastNameJoseph
           Vaccines Inc. Hernandez
Comapany
October 21,NameBlue
            2021     Water Vaccines Inc.
October
Page 2 21, 2021 Page 2
FirstName LastName
         sufficient for at least 12 months following the closing of this
offering. You further state:
         "As such, [the] pipeline projections included in the S-1 assume the
obtaining of funding
         from the offering." Particularly since your pipeline table first
appears on page 2 of the S-1
         and precedes the revised disclosure on page 4 that you reference in
your response, please
         further revise your pipeline table to indicate, by footnote including
a cross-reference or
         otherwise, that your disclosures in the "status" column of the table
assume you will obtain
         critical funding from this offering that, in combination with your
current cash position,
         you expect will allow you to continue to operate for at least 12
months following the
         closing.
We have broad discretion in the use of the net proceeds from this offering...,
page 51

2.       We note your response to prior comment 9 and your revised risk factor
disclosure on page
         51, which appears to attempt to reserve the right of management to
change the use of
         proceeds from this offering. The disclosure now states: "While we set
forth our
         anticipated use for the net proceeds from this offering in the section
titled 'Use of
         Proceeds,' our management will have broad discretion on how to use and
spend any
         proceeds that we receive from this offering and may, depending on the
outcomes of our
         preclinical studies and other research, use the proceeds in ways that
differ from the
         anticipated uses set forth in this prospectus."

         We redirect your attention to Instruction 7 to Item 504 of Regulation
S-K, which allows
         your company to reserve the right to change the use of proceeds,
provided such
         reservation is due to certain contingencies that are discussed
specifically and the
         alternatives to such use in the event of such contingencies are
indicated. Here, your
         revisions to your risk factor disclosure do not address the specific
"outcomes of [your]
         preclinical studies and other research" that could cause management to
use and spend any
         proceeds from the offering differently than stated in Use of Proceeds.
Further, the revised
         disclosure does not indicate management's intended alternative uses
for the offering
         proceeds in the event certain outcomes of preclinical studies and
other research occur.
         Therefore, please revise both your risk factor and Use of Proceeds
disclosures
         accordingly. In so doing, please ensure that the disclosures in both
sections of your
         registration statement are consistent with each other. We note that as
drafted your Use of
         Proceeds section appears to describe management's broad discretion
with respect to the
         "amounts and timing" of expenditures from the proceeds, whereas your
risk factor
         disclosure appears to more broadly describe management's discretion
with respect to the
         "use and spending" of any proceeds.

Capitalization, page 60

3.       We note your response to prior comment 9 and that you will have
2,172,371 shares of
         common stock outstanding as of September 30, 2021 (after giving effect
to the conversion
         of all outstanding shares of preferred stock into an aggregate of
1,372,371 shares). Please
 Joseph Hernandez
FirstName
Blue WaterLastNameJoseph
           Vaccines Inc. Hernandez
Comapany
October 21,NameBlue
            2021     Water Vaccines Inc.
October
Page 3 21, 2021 Page 3
FirstName LastName
         explain to us how you calculated the conversion of the 1,146,138
outstanding preferred
         stock into 1,372,271 shares considering the issuance price and
conversion are the same.
4.       We note on page F-15 that each Series Seed is automatically converted
into common
         stock of the company, at a conversion price of $6.09 per share,
subject to adjustment,
         upon the closing a firmly underwritten public offering netting
proceeds of at least
         $50 million with an offering price of at least three hundred percent
(300%) of the Original
         Issue Price of the Series Seed. Please explain to us how you will meet
the conversion
         requirements for the Series Seed preferred stock to convert upon your
IPO.
Our Vaccine Platform
Structure, page 80

5.       We note your response to prior comment 13. While you have removed one
reference to
         "potent" and replaced it with the word "strong" at the top of page 81,
we note that a new
         reference to "potent platforms" has been added on page 80. Further, we
note that the
         reference to "potent" remains in a sub-section heading on page 82
("S60 nanoparticles
         may serve as a polyvalent potent vaccine platform"). While you have
insert a citation to a
         published study in this sub-section heading, it is unclear whether the
results of such cited
         study related to the potency of the vaccine platform that S60
nanoparticles "may"
         provide. In relation to these references to "potent" platforms, we
reissue the prior
         comment.
6.       We refer to the second bullet on page 80 which states: "There are
several preclinical
         animal studies have showed P24/S60 chimeric vaccine candidates have
high protective
         effects against viral pathogens or diseases. As set forth below in
Table 1."
             Please revise Table 1 and any other tables or graphics throughout
your filing to
             ensure that the text in each, including subscript or other
notations are clearly legible.
             Please revise your disclosure and/or your table to clarify what
Table 1 on page 81 is
             intended to reflect. We note that the items shown in the table
should be easily
             identifiable from and tie to the description of those items in the
disclosure above.
             While your bulleted disclosure on page 80 references references
"several preclinical
             animal studies," it is not clear which studies are being referred
to and how they may
             relate to information in Table 1. Further, the bulleted disclosure
preceding the table
             indicates that such animal studies "showed that P24/S60 chimeric
vaccine candidates
             have high protective effects against viral pathogens or diseases,"
but the level or
             degree of protective effect does not appear to shown in Table 1.
             Please also revise to clarify what the numbers in the column
labeled "Reference" in
             Table 1 on page 81 mean.

         Additionally, we note that another table captioned "Table 1" has been
added in this section
         on page 82.
             To aid investor understanding and for the avoidance of confusion,
please renumber
             the second table on page 82.
             The same comment given with respect to the Table 1 included on
page 81 applies.
 Joseph Hernandez
FirstName
Blue WaterLastNameJoseph
           Vaccines Inc. Hernandez
Comapany
October 21,NameBlue
            2021     Water Vaccines Inc.
October
Page 4 21, 2021 Page 4
FirstName LastName
              Please revise to clearly tie the information presented in the
table to your disclosure.
                We note that you appear to have included footnote citations
(a)    through "(e)" in the
              column labeled "epitope/antigen," and there appears to be a
footnote citation "(f)" in
              the heading for the column labeled "significant immune
enhancement in mice."
              However, in each case there is no corresponding footnote
disclosure under the table.
              Please revise as appropriate. Additionally, please indicate, by
footnote or otherwise,
              what the acronyms or abbreviations in the "epitope/antigen"
column mean as you did
              in the table included on page 81.
                It is unclear what "ND" in the column labeled "significant
immune enhancement in
              mice" means. Please revise to provide explanatory disclosure in
order for an investor
              to understand the table.

BWV-201 Streptococcus pneumoniae (S. pneumoniae) Vaccine, page 88

7.       We note your response to second part of prior comment 17. Please
revise your disclosure
         and/or Figure A on page 90 to help investors better understand the
preclinical head-to-
         head results your response notes you have included to compare your
vaccine strain to
         Prevnar 7, Prevnar 13 and Pneumovax. For example, the names of the
vaccines and
         strains shown on the x-axis in the graph should be easily identifiable
from and tie to the
         description of those items in the narrative disclosure above the
graph. Explain what
         "Percent" on the y-axis measures.
BWV-302: Norovirus-malaria vaccine program, page 95

8.       We acknowledge the addition of disclosure beginning on page 95
regarding your BWV-
         302 vaccine program for Norovirus-Malaria in response to prior comment
5. We have the
         following additional comments:
             In the first paragraph in this section captioned "Our Vaccine,"
please revise to
              provide additional context for the following statement: "The
researchers, Xi Jason
              Jiang, Ph.D., and Ming Tan, Ph.D., demonstrated that S60 VLPs
could be used to
              present foreign antigens on the surface of the S60 VLP. Further,
it has also
              demonstrated that foreign antigens could also be expressed on the
surface of the P24
              VLP." Please explain how the co-researchers for your
norovirus-malaria
              combination vaccine "demonstrated" these findings by briefly
describing the
              researchers' relevant work or studies.
             The last sentence in "Our Vaccine" states as follows with respect
to your mouse
              immunization study: "These data demonstrate the potential of our
vaccine candidate
              against malaria." Based on your disclosure in the "status" column
of your pipeline
              table for BWV-302, which indicates that you intend to begin
IND-enabling studies
              for BWV-302 in the second half of 2022, it appears that you do
not expect to be able
              to rely on this mouse immunization study data data to support an
IND application.
              Please revise your disclosure to briefly explain what additional
pre-IND enabling
              studies or steps you expect to have to conduct or take prior to
proceeding with IND-
 Joseph Hernandez
FirstName
Blue WaterLastNameJoseph
           Vaccines Inc. Hernandez
Comapany
October 21,NameBlue
            2021     Water Vaccines Inc.
October
Page 5 21, 2021 Page 5
FirstName LastName
              enabling studies.
                The paragraph in this section captioned "Development" states as
follows: "Following
              IND submission, if accepted, we intend to initiate our Phase I
clinical trial in healthy
              adults ages 18 to 54 in the first half of 2023." We note that you
disclose your
              intended timing of Phase 1 clinical trials for BWV-302 without
having first addressed
              when you plan to submit your IND application. Given the early
stage of development
              for this candidate, and your statement in your pipeline table
that you do not plan to
              initiate IND-enabling studies for this candidate until the second
half of 2022, this
              statement regarding clinical trial commencement is premature and
speculative and
              should be removed.
Intellectual Property, page 114

9.       We note your response to prior comment 18. We have the following
additional comments:
             With respect to your pending patent applications, please revise
the disclosure in your
            various tabular presentations to disclose the type of patent
protection sought for each
            product or technology (composition of matter, use, or process).
             We note your disclosure that the CHMC license agreement may end
upon the last-to-
            expire patent on a jurisdiction by jurisdiction and product by
product basis. Please
            revise your tabular presentation of the issued and pending patents
under
            this agreement to clarify when the last of these patents are
expected to expire in both
            the U.S. and any foreign jurisdictions.
10.      We note your revisions in response to prior comment 19, which we
reissue. Revise your
         disclosures regarding each of your license and option agreements to
include a discussion
         of all material payment terms, including quantification of the
following:
             Up-front or execution payments paid or received. In this regard,
we refer you by way
              of example and not limitation to phrases such as "a one-time
five-digit initial license
              fee" on page 115.
             Annual maintenance fees.
             Aggregate amounts paid or received.
             Aggregate future potential milestone payments to be paid or
received.
             Profit or revenue-sharing provisions.
             Applicable royalty rates to be paid by each party. In the event a
range is provided in
              place of the actual royalty rate, such range should be within ten
percentage points. In
              this regard, we refer you to your reference on page 117 to
"double-digit royalties to
              be paid on any sums received by the Company from any sublicensee
under the terms
              of the OUI Agreement" and on page 119 to the Company's obligation
to pay "a
              double-digit percentage of other consideration received for any
sublicenses" under
              the St. Jude License Agreement. Also, with respect to the OUI
license agreement,
              please revise your disclosure on page 118 to state the highest
"minimum sum" of
              royalties that must be paid to OUI in any year before application
of the "step down."
              Please disclose the period of years over which the step-down will
apply before the
              minimum sum is reduced to zero.
 Joseph Hernandez
Blue Water Vaccines Inc.
October 21, 2021
Page 6

      Additionally, please revise your IP disclosure to define acronyms at
first use. For
      instance, we note that in a description of a development milestone on
page 115, you use
      the acronym "first commercial sale in ROW" without defining "ROW," which
appears
      again later in this section.
11.   We note your revisions in response prior comment 20, and that you have
now disclosed
      the "minimum" amount of funding the Company provided to Oxford University
in
      January 2020 for three years of salary for Dr. Craig Thompson as a
condition of entering
      into the OUI license agreement. To the extent known, please revise your
disclosure to
      provide the maximum amount that the Company may be required to pay to
fund three
      years of salary for Dr. Craig Thompson, and when such additional
payment(s) will be
      due. Disclose any factors that will impact the amount of annual salary
for the relevant
      three-year period so as to determine the ultimate amount the Company will
be obligated to
      pay, or advise.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Tara Harkins at 202-551-3639 or Mary Mast at
202-551-3613 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Lauren Hamill at 303-844-1008 or Celeste Murphy at 202-551-3257 with
any other
questions.



                                                           Sincerely,
FirstName LastNameJoseph Hernandez
                                                           Division of
Corporation Finance
Comapany NameBlue Water Vaccines Inc.
                                                           Office of Life
Sciences
October 21, 2021 Page 6
cc:       Jessica Yuan
FirstName LastName
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
